References
- Halatchev IG, Zheng J, Ou J. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis. 2018;10(3):2034–2045.
- Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043.
- Fukunishi S, Nishio S, Takeda Y, et al. Treatment strategy for amyloid hip arthropathy in long-term hemodialysis patients. J Orthop Sci. 2017;22(5):898–904.
- Elsaman AM, Radwan AR, Akmatov MK, et al. Amyloid arthropathy associated with multiple myeloma: a systematic analysis of 101 reported cases. Semin Arthritis Rheum. 2013;43(3):405–412.
- M'Bappé P, Grateau G. Osteo-articular manifestations of amyloidosis. Best Pract Res Clin Rheumatol. 2012;26(4):459–475.
- Uchihara Y, Iwata E, Papadimitriou-Olivgeri I, et al. Localised foot and ankle amyloid deposition. Pathol Res Pract. 2018;214(10):1661–1666.
- Tsujii A, Nakamura N, Horibe S. Age-related changes in the knee meniscus. Knee. 2017;24(6):1262–1270.
- Akasaki Y, Reixach N, Matsuzaki T, et al. Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis. Arthritis Rheumatol. 2015;67(8):2097–2107.
- Takinami Y, Yoshimatsu S, Uchiumi T, et al. Identification of potential prognostic markers for knee osteoarthritis by serum proteomic analysis. Biomark Insights. 2013;8:85–95.
- Gu YJ, Ge P, Mu Y, et al. Clinical and laboratory characteristics of patients having amyloidogenic transthyretin deposition in osteoarthritic knee joints. J Zhejiang Univ Sci B. 2014;15(1):92–99.
- Yanagisawa A, Ueda M, Sueyoshi T, et al. Knee osteoarthritis associated with different kinds of amyloid deposits and the impact of aging on type of amyloid. Amyloid. 2016;23(1):26–32.
- Jørgensen AEM, Kjaer M, Heinemeier KM. The effect of aging and mechanical loading on the metabolism of articular cartilage. J Rheumatol. 2017;44(4):410–417.
- Amin HZ, Mori S, Sasaki N, et al. Diagnostic approach to cardiac amyloidosis. Kobe J Med Sci. 2014;60(1):E5–E11.
- Sekijima Y, Yazaki M, Ueda M, et al. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid. 2018;25(1):8–10.
- Sato S, Seki H, Ikeda SI. Hereditary amyloid polyneuropathy-related destructive arthropathy in a hip joint. Amyloid. 2017;24(1):64–65.
- Shiraishi M, Ando Y, Mizuta H, et.al. Charcot knee arthropathy with articular amyloid deposition in familial amyloidotic polyneuropathy. Scand J Rheumatol. 1997;26(1):61–64.
- Takanashi T, Matsuda M, Yazaki M, et al. Synovial deposition of wild-type transthyretin-derived amyloid in knee joint osteoarthritis patients. Amyloid. 2013;20(3):151–155.
- Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol. 2011;24(12):1533–1544.
- Matsuzaki T, Akasaki Y, Olmer M, et.al. Transthyretin deposition promotes progression of osteoarthritis. Aging Cell. 2017;16(6):1313–1322.
- Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J. Am. Soc. Nephrol. 2002;13(5):1296–1306.
- Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey:initial report on clinical manfestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76.
- Lam L, Margeta M, Layzer R. Amyloid polyneuropathy caused by wild-type transthyretin. Muscle Nerve. 2015;52(1):146–149.
- Rigopoulos AG, Ali M, Abate E, et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail Rev. 2019;24(4):521–533.
- Lamb YN, Deeks ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79(8):863–874.
- Ishii T, Sekijima Y, Ando Y. Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan – interim analysis in post-marketing surveillance. Amyloid. 2019;26(sup1):45–46.